Luminal-B breast cancer and novel therapeutic targets

Gene expression profiling has led to a new molecular classification of breast cancer characterized by four intrinsic subtypes: basal-like; erbB2/HER2-positive; luminal-A; and luminal-B. Despite expressing estrogen receptor, the luminal-B subtype confers increased risk of early relapse with endocrine therapy compared to luminal-A.

Although luminal-B definitions vary, the hallmark appears to be increased expression of proliferation-related genes. Several biological pathways are identified as possible contributors to the poor outcomes and novel agents targeting these pathways are being developed with aims to improve survival.

We review the definition of luminal-B breast cancer, its pathological and clinical features and potential targets for treatment.

Author: Ben TranPhilippe L Bedard
Credits/Source: Breast Cancer Research 2011, 13:221

Published on: 2011-11-30

Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.

Comments Page 0 of 0

There are currently 0 comments to display.

+ Add New Comment

Custom Search